Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cop 1 as a candidate drug for multiple sclerosis

D Teitelbaum1, R Arnon, M Sela

  • 1Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.

Journal of Neural Transmission. Supplementum
|January 1, 1997
PubMed
Summary

Copolymer 1 (Cop 1) effectively suppresses experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis (MS). Clinical trials show Cop 1 significantly benefits MS patients with minimal side effects, indicating its promise as a therapeutic agent.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy.

Multiple sclerosis (Houndmills, Basingstoke, England)·2003
Same author

Technique for fabrication of splint preventing postsurgical restenosis in choanal atresia.

The Journal of prosthetic dentistry·2003
Same author

Harnessing the osseointegration principle for anchorage of fingernail prostheses.

Hand clinics·2003
Same author

[The use of Dental D (polyacetal resin) as an alternative for chrome-cobalt removable partial denture: a case report].

Refu'at ha-peh veha-shinayim (1993)·2002
Same author

Metastatic hypernephroma to the head and neck: unusual case reports and review of the literature.

The Journal of otolaryngology·2002
Same author

The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes.

Proceedings of the National Academy of Sciences of the United States of America·2001

Area of Science:

  • Neuroimmunology
  • Autoimmune Diseases
  • Pharmacology

Background:

  • Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Experimental Autoimmune Encephalomyelitis (EAE) serves as a primary animal model for studying MS pathogenesis and therapeutic interventions.
  • Copolymer 1 (Cop 1), a synthetic amino acid polymer, has demonstrated immunomodulatory properties.

Purpose of the Study:

  • To evaluate the efficacy and safety of Copolymer 1 (Cop 1) in suppressing Experimental Autoimmune Encephalomyelitis (EAE).
  • To assess the therapeutic potential of Cop 1 in a clinical setting for relapsing-remitting Multiple Sclerosis (MS) patients.

Main Methods:

  • Cop 1's ability to suppress EAE was assessed in various animal species, including primates.

Related Experiment Videos

  • Phase II and Phase III clinical trials were conducted in relapsing-remitting MS patients.
  • A multicenter, double-blind, placebo-controlled trial involving 251 patients over two years was performed.

    • Main Results:

    • Cop 1 demonstrated significant suppression of EAE, indicating its immunomodulatory capacity.
    • Clinical trials revealed that Cop 1 significantly reduced exacerbation rates and improved clinical status in MS patients.
    • The treatment with Cop 1 was associated with minimal adverse side effects.

    Conclusions:

    • Copolymer 1 (Cop 1) is a safe and effective therapeutic agent for Multiple Sclerosis (MS).
    • Cop 1's mechanism involves immunological cross-reactivity with myelin basic protein (MBP), inducing suppressor cells and competing for MHC binding.
    • Cop 1 represents a promising drug candidate for the management of MS.